A
Atsushi Nakajima
Researcher at Kyoto Prefectural University of Medicine
Publications - 8
Citations - 413
Atsushi Nakajima is an academic researcher from Kyoto Prefectural University of Medicine. The author has contributed to research in topics: Nonalcoholic fatty liver disease & Liver biopsy. The author has an hindex of 3, co-authored 8 publications receiving 325 citations. Previous affiliations of Atsushi Nakajima include Otsuka Pharmaceutical.
Papers
More filters
Journal ArticleDOI
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
TL;DR: The NAFIC score, calculated from the levels of ferritin, fasting insulin, and type IV collagen 7S, is useful for the diagnosis of NASH, while the NAFLD fibrosis score and the FIB-4 index are useful for excluding NASH in cases of advanced fibrosis.
Posted ContentDOI
FIB-4 First in Diagnostic Algorithm of MAFLD at the Era of “Global Metabodemic “
Yoshio Sumida,Masashi Yoneda,Katsutoshi Tokushige,Miwa Kawanaka,Hideki Fujii,Masato Yoneda,Kento Imajo,Hirokazu Takahashi,Yuichiro Eguchi,Masafumi Ono,Yuichi Nozaki,Hideyuki Hyogo,Masahiro Koseki,Yuichi Yoshida,Takumi Kawaguchi,Yoshihiro Kamada,Takeshi Okanoue,Atsushi Nakajima +17 more
TL;DR: The role of FIB-4 index as 1st step NIT in management of NAFLD is reviewed, which could be a predictor of not only liver-related mortality and incident hepatocullar carcinoma (HCC) but also prevalent and incident CKD, CVD, and extrahepatic malignancy.
Book ChapterDOI
Acoustic Radiation Force Impulse Elastography: A Non-Invasive Alternative to Liver Biopsy
Hirokazu Takahashi,Naofumi Ono,Yuichiro Eguchi,Toshihiko Mizuta,Keizo Anzai,Atsushi Miyoshi,Masato Yoneda,Atsushi Nakajima,Kazuma Fujimoto +8 more
TL;DR: A safe and non-invasive alternative to liver biopsy is therefore needed for assessing liver fibrosis in daily clinical practice.
Patent
Carbostyril derivatives including cilostazol for treating fatty liver
TL;DR: In this paper, a medicament for preventing and/or treating fatty liver which comprises as an active ingredient cilostazol or a pharmaceutically acceptable salt thereof is described.
Journal ArticleDOI
Norursodeoxycholic acid as a candidate pharmacological therapy for nonalcoholic fatty liver disease
Masato Yoneda,Atsushi Nakajima +1 more
TL;DR: The medical need for an effective pharmacological treatment for NAFLD/NASH must be met, and a dose-dependent reduction in serum ALT in patients treated with norursodeoxycholic acid (norUDCA) is shown.